🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

198 results for “Novartis Ophthalmics Europe” Clear

  1. Placebo 0 mg hard gelatin capsule size 1, (placebo to lnp023 100 mg), Placebo 0 mg hard gelatin capsule size 0, (placebo to lnp023 200 mg), IPTACOPAN HYDROCHLORIDE, IPTACOPAN

    Novartis Ophthalmics Europe

    complement 3 glomerulopathy

    phase 3 small molecule active

    1 trial

  2. Placebo 0 mg/1 mL Solution for infusion/injection, VAY736

    Novartis Ophthalmics Europe

    Autoimmune hepatitis

    phase 3 small molecule active

    1 trial

  3. Placebo to AIN457 150 mg/ 1 mL Solution for injection in pre-filled syringe. This placebo is an additional/ alternative placebo to placebo to Xolair® (Omalizumab) to ensure continuous supply in the clinical trial. For more details please refer to Note to Assessor located in the “Placebo to AIN457” product shell., OMALIZUMAB , -, Placebo to Xolair® (Omalizumab) 150 mg/ml solution for injection in pre-filled syringe, LOU064, Placebo to Remibrutinib (LOU064) 25 mg film-coated tablet, -

    Novartis Ophthalmics Europe

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  4. Placebo to AIN457 300 mg/2 mL Solution for injection in pre-filled syringe, Cosentyx 300 mg solution for injection in pre-filled syringe

    Novartis Ophthalmics Europe

    Giant Cell Arteritis

    phase 3 small molecule active

    1 trial

  5. Placebo to AIN457 300mg/2mL Solution for injection in pre-filled syringe, SECUKINUMAB

    Novartis Ophthalmics Europe

    Hidradenitis suppurativa

    phase 3 small molecule active

    1 trial

  6. Placebo to Remibrutinib (LOU064) 0 mg matching 00 mg film-coated tablet, TRIAMCINOLONE , Placebo to Remibrutinib (LOU064) 0 mg matching 00 mg film-coated tablet, LOU064, CLINDAMYCIN , LOU064, -

    Novartis Ophthalmics Europe

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  7. Placebo to Remibrutinib (LOU064) 00 mg film-coated tablet, LOU064

    Novartis Ophthalmics Europe

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  8. Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, LOU064, LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet

    Novartis Ophthalmics Europe

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  9. Placebo to Remibrutinib (LOU064) film-coated tablets, LOU064

    Novartis Ophthalmics Europe

    Secondary progressive multiple sclerosis

    phase 3 small molecule active

    1 trial

  10. Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device, TQJ230

    Novartis Ophthalmics Europe

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  11. Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, VAY736, -

    Novartis Ophthalmics Europe

    Sjögren’s Syndrome

    phase 3 small molecule active

    1 trial

  12. Placebo to remibrutinib (LOU064) 25 mg film-coated tablet, -, LOU064, -

    Novartis Ophthalmics Europe

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  13. ROSUVASTATIN, INCLISIRAN, ATORVASTATIN, ATORVASTATIN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ROSUVASTATIN

    Novartis Ophthalmics Europe

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  14. ROSUVASTATIN, ROSUVASTATIN, INCLISIRAN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN

    Novartis Ophthalmics Europe

    Non-obstructive Coronary Artery Disease

    phase 3 small molecule active

    1 trial

  15. SECUKINUMAB

    Novartis Ophthalmics Europe

    Polymyalgia Rheumatica

    phase 3 small molecule active

    1 trial

  16. SEG101

    Novartis Ophthalmics Europe

    Sickle cell disease

    phase 3 small molecule active

    1 trial

  17. TENOFOVIR DISOPROXIL , ENTECAVIR , VAY736, -, Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, TENOFOVIR ALAFENAMIDE

    Novartis Ophthalmics Europe

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  18. TERIFLUNOMIDE, INTERFERON BETA-1A, DIROXIMEL FUMARATE, INTERFERON BETA-1A, INTERFERON BETA-1A, GLATIRAMER ACETATE, Betaferon 250 microgram/ml, powder and solvent for solution for injection, OFATUMUMAB, GLATIRAMER ACETATE, DIMETHYL FUMARATE, PEGINTERFERON BETA-1A, DIMETHYL FUMARATE

    Novartis Ophthalmics Europe

    relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  19. TQJ230

    Novartis Ophthalmics Europe

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  20. TQJ230, INCLISIRAN, Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device

    Novartis Ophthalmics Europe

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  21. TQJ230, Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device

    Novartis Ophthalmics Europe

    Apheresis

    phase 3 small molecule active

    1 trial

  22. Tasigna 200 mg hard capsules, DASATINIB, IMATINIB, DASATINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, IMATINIB, DASATINIB, NILOTINIB, BOSUTINIB, BOSUTINIB, Tasigna 150 mg hard capsules, DASATINIB, Tasigna 150 mg hard capsules, Tasigna 150 mg hard capsules, IMATINIB, Tasigna 150 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 150 mg hard capsules, Tasigna 200 mg hard capsules, ASCIMINIB HYDROCHLORIDE, Tasigna 200 mg hard capsules

    Novartis Ophthalmics Europe

    chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  23. VAY736, -, Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe

    Novartis Ophthalmics Europe

    Sjögren’s Syndrome

    phase 3 small molecule active

    1 trial

  24. VAY736, ENTECAVIR , Placebo to VAY736, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -

    Novartis Ophthalmics Europe

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources